Recent developments on JAK2 inhibitors: a patent review

By Kiss Róbert   Sayeski Peter P   Keserű György M  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 4, 2010-04 ,pp. : 471-495

Informa Healthcare

Access to resources Recommend Favorite

JAK2 inhibitors in the treatment of myeloproliferative neoplasms

By Tibes Raoul   Bogenberger James M   Geyer Holly L   Mesa Ruben A  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1755-1774

Informa Healthcare

Access to resources Recommend Favorite

New JAK2 inhibitors for myeloproliferative neoplasms

By Quintáás-Cardama Alfonso   Verstovsek Srdan  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 7, 2011-07 ,pp. : 961-972

Informa Healthcare

Access to resources Recommend Favorite

Cyclooxygenase-2 inhibitors: a literature and patent review (2009 – 2010)

By Jawabrah Al-Hourani Baker   Sharma Sai Kiran   Suresh Mavanur   Wuest Frank  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 9, 2011-09 ,pp. : 1339-1432

Informa Healthcare

Access to resources Recommend Favorite

Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors

By  

Clinical Cancer Drugs, Vol. 3, Iss. 2, 2016-10 ,pp. : 131-137

Bentham Science Publishers

Access to resources Recommend Favorite